Apiam Animal Health
- Home
- Apiam Animal Health
Public
Opening a new frontier in treating Parkinson’s disease
- Review
- November 11, 2022
Is this the most hated company on the ASX?
- Review
- August 16, 2019
Latest Articles
Bruce Dixon and Vita Pepe syndicate takes major position in Apiam Animal Health
An investor syndicate featuring the well known names of Bruce Dixon and Vita Pepe have identified vet clinic operator Apiam Animal Health (ASX: AHX) as their next investment project after acquiring 13.44% of the Company. On Wednesday, AHX shares were strangely active with 15% of the Company changing hands and no fanfare in a move
Read MorePublic
Apiam Animal Health delivers record earnings, leverages animal data analytics and streamlines business to drive growth
Australians may have been cutting costs through FY24 as evidenced by discretionary spending behaviour but this has played right into the hands of Apiam Animal Health (ASX: AHX) which has seen a surge in customers to its all-inclusive Best Mates membership program which is up 32% to 11,300 members. Rather than paying for each visit
Read MorePublic
Apiam deploys revolutionary tick and flea preventative for Australian dog owners, a major growth driver for FY25
Australian pet owners now have access to revolutionary tick and flea preventative with vet clinic operator Apiam Animal Health (ASX: AHX) having commenced sales of the injectable treatment which provides up to 12 months of control of paralysis ticks and treatment and prevention from flea infestations. The new technology was developed by pharmaceuticals giant Merck
Read MorePublic
Apiam Animal Health partners with Veyx-Pharma to distribute innovative products in Australia
Apiam Animal Health (ASX: AHX) has announced a strategic partnership with the German company Veyx-Pharma to distribute their cutting-edge products across Australia. This agreement marks a significant milestone for both companies as they expand their reach and bring new technology to the Australian market. Over the past six months, Apiam has been rigorously researching Veyx-Pharma’s
Read MorePublic
Australians putting animals first as Apiam revenue and earnings resilience defy economic headwinds
Despite the economic squeeze Australians are under due to inflationary pressures, pet owners are prioritising spend on health and wellness as reflected by vet clinic operator Apiam Animal Health (ASX: AHX) in their March quarter update. For the 9 months ended 31 March 2024, Apiam reported $154.8 million revenue which represented a 8.5% increase on
Read MorePublic
Small cap MD buys $1 million of shares with no discount as business transformation takes shape
In the backstretch of a business transformation that has consolidated their nationwide business and resumed shareholder dividends, one small cap Managing Director is so confident in the progress that he has personally backed the Company’s growth, purchasing $1.0 million in shares. The show of confidence comes from Dr Chris Richards, Managing Director and CEO of
Read MorePublic
